Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation

Alison M. Friedmann, Melissa M. Hudson, Howard J. Weinstein, Sarah S. Donaldson, Larry Kun, Nancy J. Tarbell, Michael P. Link

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: Between January 1990 and April 1993, 56 pediatric patients with Hodgkin's disease were treated on a single-arm trial at three institutions with a regimen designed to maintain high cure rates while minimizing the potential late effects of treatment, such as infertility, second malignant neoplasms, and cardiopulmonary injury. Patients and Methods: The regimen used combined-modality therapy with six cycles of vinblastine, etoposide, prednisone, and doxorubicin (VEPA) chemotherapy and low-dose, involved-field radiation. Unfavorable features comprised bulky presentations of localized (stage I or II) disease or advanced (stage III or IV) Hodgkin's disease. Results: Of 56 patients enrolled, 26 (46%) had unfavorable presentations of stage I/II disease and 30 (54%) had advanced (stage III/IV) disease. Seventy-nine percent of the patients are alive without disease at a median follow-up time of 8.9 years from diagnosis. Nineteen patients had events at a median of 1.5 years (range, 0.4 to 7.9 years) from diagnosis; 17 patients relapsed, one died of cardiomyopathy, and one died of accidental injuries. Survival and event-free survival (EFS) estimates at 5 years for the entire cohort were 81.9% (SE, 5.2%) and 67.8% (SE, 6.3%), respectively. Five-year EFS by stage was 100% for stage I, 79.2% (SE, 8.3%) for stage II, 70% (SE, 14.5%) for stage III, and 49.5% (SE, 11.3%) for stage IV patients. Conclusion: Combined-modality therapy with VEPA chemotherapy and low-dose, involved-field radiation is adequate for disease control of early-stage patients with unfavorable features, but it is inferior to other standard regimens for advanced-stage patients.

Original languageEnglish (US)
Pages (from-to)3088-3094
Number of pages7
JournalJournal of Clinical Oncology
Volume20
Issue number14
DOIs
StatePublished - Jul 15 2002

Fingerprint

Vinblastine
Etoposide
Prednisone
Hodgkin Disease
Doxorubicin
Radiation
Combined Modality Therapy
Therapeutics
Disease-Free Survival
Drug Therapy
Second Primary Neoplasms
Wounds and Injuries
Cardiomyopathies
Infertility
Pediatrics
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Friedmann, A. M., Hudson, M. M., Weinstein, H. J., Donaldson, S. S., Kun, L., Tarbell, N. J., & Link, M. P. (2002). Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. Journal of Clinical Oncology, 20(14), 3088-3094. https://doi.org/10.1200/JCO.2002.03.051

Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. / Friedmann, Alison M.; Hudson, Melissa M.; Weinstein, Howard J.; Donaldson, Sarah S.; Kun, Larry; Tarbell, Nancy J.; Link, Michael P.

In: Journal of Clinical Oncology, Vol. 20, No. 14, 15.07.2002, p. 3088-3094.

Research output: Contribution to journalArticle

Friedmann, AM, Hudson, MM, Weinstein, HJ, Donaldson, SS, Kun, L, Tarbell, NJ & Link, MP 2002, 'Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation', Journal of Clinical Oncology, vol. 20, no. 14, pp. 3088-3094. https://doi.org/10.1200/JCO.2002.03.051
Friedmann AM, Hudson MM, Weinstein HJ, Donaldson SS, Kun L, Tarbell NJ et al. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. Journal of Clinical Oncology. 2002 Jul 15;20(14):3088-3094. https://doi.org/10.1200/JCO.2002.03.051
Friedmann, Alison M. ; Hudson, Melissa M. ; Weinstein, Howard J. ; Donaldson, Sarah S. ; Kun, Larry ; Tarbell, Nancy J. ; Link, Michael P. / Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 14. pp. 3088-3094.
@article{2366f2b4aeba4e76a4d3e55fa2bd02c4,
title = "Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation",
abstract = "Purpose: Between January 1990 and April 1993, 56 pediatric patients with Hodgkin's disease were treated on a single-arm trial at three institutions with a regimen designed to maintain high cure rates while minimizing the potential late effects of treatment, such as infertility, second malignant neoplasms, and cardiopulmonary injury. Patients and Methods: The regimen used combined-modality therapy with six cycles of vinblastine, etoposide, prednisone, and doxorubicin (VEPA) chemotherapy and low-dose, involved-field radiation. Unfavorable features comprised bulky presentations of localized (stage I or II) disease or advanced (stage III or IV) Hodgkin's disease. Results: Of 56 patients enrolled, 26 (46{\%}) had unfavorable presentations of stage I/II disease and 30 (54{\%}) had advanced (stage III/IV) disease. Seventy-nine percent of the patients are alive without disease at a median follow-up time of 8.9 years from diagnosis. Nineteen patients had events at a median of 1.5 years (range, 0.4 to 7.9 years) from diagnosis; 17 patients relapsed, one died of cardiomyopathy, and one died of accidental injuries. Survival and event-free survival (EFS) estimates at 5 years for the entire cohort were 81.9{\%} (SE, 5.2{\%}) and 67.8{\%} (SE, 6.3{\%}), respectively. Five-year EFS by stage was 100{\%} for stage I, 79.2{\%} (SE, 8.3{\%}) for stage II, 70{\%} (SE, 14.5{\%}) for stage III, and 49.5{\%} (SE, 11.3{\%}) for stage IV patients. Conclusion: Combined-modality therapy with VEPA chemotherapy and low-dose, involved-field radiation is adequate for disease control of early-stage patients with unfavorable features, but it is inferior to other standard regimens for advanced-stage patients.",
author = "Friedmann, {Alison M.} and Hudson, {Melissa M.} and Weinstein, {Howard J.} and Donaldson, {Sarah S.} and Larry Kun and Tarbell, {Nancy J.} and Link, {Michael P.}",
year = "2002",
month = "7",
day = "15",
doi = "10.1200/JCO.2002.03.051",
language = "English (US)",
volume = "20",
pages = "3088--3094",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation

AU - Friedmann, Alison M.

AU - Hudson, Melissa M.

AU - Weinstein, Howard J.

AU - Donaldson, Sarah S.

AU - Kun, Larry

AU - Tarbell, Nancy J.

AU - Link, Michael P.

PY - 2002/7/15

Y1 - 2002/7/15

N2 - Purpose: Between January 1990 and April 1993, 56 pediatric patients with Hodgkin's disease were treated on a single-arm trial at three institutions with a regimen designed to maintain high cure rates while minimizing the potential late effects of treatment, such as infertility, second malignant neoplasms, and cardiopulmonary injury. Patients and Methods: The regimen used combined-modality therapy with six cycles of vinblastine, etoposide, prednisone, and doxorubicin (VEPA) chemotherapy and low-dose, involved-field radiation. Unfavorable features comprised bulky presentations of localized (stage I or II) disease or advanced (stage III or IV) Hodgkin's disease. Results: Of 56 patients enrolled, 26 (46%) had unfavorable presentations of stage I/II disease and 30 (54%) had advanced (stage III/IV) disease. Seventy-nine percent of the patients are alive without disease at a median follow-up time of 8.9 years from diagnosis. Nineteen patients had events at a median of 1.5 years (range, 0.4 to 7.9 years) from diagnosis; 17 patients relapsed, one died of cardiomyopathy, and one died of accidental injuries. Survival and event-free survival (EFS) estimates at 5 years for the entire cohort were 81.9% (SE, 5.2%) and 67.8% (SE, 6.3%), respectively. Five-year EFS by stage was 100% for stage I, 79.2% (SE, 8.3%) for stage II, 70% (SE, 14.5%) for stage III, and 49.5% (SE, 11.3%) for stage IV patients. Conclusion: Combined-modality therapy with VEPA chemotherapy and low-dose, involved-field radiation is adequate for disease control of early-stage patients with unfavorable features, but it is inferior to other standard regimens for advanced-stage patients.

AB - Purpose: Between January 1990 and April 1993, 56 pediatric patients with Hodgkin's disease were treated on a single-arm trial at three institutions with a regimen designed to maintain high cure rates while minimizing the potential late effects of treatment, such as infertility, second malignant neoplasms, and cardiopulmonary injury. Patients and Methods: The regimen used combined-modality therapy with six cycles of vinblastine, etoposide, prednisone, and doxorubicin (VEPA) chemotherapy and low-dose, involved-field radiation. Unfavorable features comprised bulky presentations of localized (stage I or II) disease or advanced (stage III or IV) Hodgkin's disease. Results: Of 56 patients enrolled, 26 (46%) had unfavorable presentations of stage I/II disease and 30 (54%) had advanced (stage III/IV) disease. Seventy-nine percent of the patients are alive without disease at a median follow-up time of 8.9 years from diagnosis. Nineteen patients had events at a median of 1.5 years (range, 0.4 to 7.9 years) from diagnosis; 17 patients relapsed, one died of cardiomyopathy, and one died of accidental injuries. Survival and event-free survival (EFS) estimates at 5 years for the entire cohort were 81.9% (SE, 5.2%) and 67.8% (SE, 6.3%), respectively. Five-year EFS by stage was 100% for stage I, 79.2% (SE, 8.3%) for stage II, 70% (SE, 14.5%) for stage III, and 49.5% (SE, 11.3%) for stage IV patients. Conclusion: Combined-modality therapy with VEPA chemotherapy and low-dose, involved-field radiation is adequate for disease control of early-stage patients with unfavorable features, but it is inferior to other standard regimens for advanced-stage patients.

UR - http://www.scopus.com/inward/record.url?scp=0037099626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037099626&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.03.051

DO - 10.1200/JCO.2002.03.051

M3 - Article

C2 - 12118022

AN - SCOPUS:0037099626

VL - 20

SP - 3088

EP - 3094

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -